Login / Register The Most Trusted Name in Medical Education

Dermatology

Look no further for the gold standard in dermatology continuing medical education. Receive AMA PRA Category 1 Credit™ for taking any of our complimentary courses.

910791 116 x 140

The Role of Oncolytic Viral Therapy in the Management of Patients with Metastatic Melanoma

Format: Webcast

This CME program will delve into the role of oncolytic viral therapy in the treatment and management of the metastatic melanoma patients, highlighting data presented at the Maui and Hawaii Dermatology 2018 annual meetings. The three expert faculty will review the immunotherapy for melanoma, followed by a discussion of recent safety and efficacy trial data for this emerging therapeutic option. Practical strategies for safely utilizing oncolytic viral therapies in clinical practice as well as best practices for engaging the interprofessional team will be relayed to the learner through an discussion-based format.

*This webcast is not endorsed by the conference organizer. Elsevier Office of Continuing Medical Education is an independent medical education company that provides clinical updates, analysis and expert perspectives through conference coverage educational programs.

Take Course »

 

Credits: 1.0 AMA PRA Category 1 Credit™
910722e 116 x 140

HOW IMMUNE CHECKPOINT INHIBITORS ARE CHANGING THE TREATMENT LANDSCAPE FOR METASTATIC MELANOMA

Format: Webcast

Metastatic melanoma has a high mortality rate and is refractory to traditional treatments, but recent clinical trials have shown significantly improved patient outcomes with checkpoint inhibitors. However, treating physicians may find its use challenging due to limited clinical experience and confidence in prescribing immunotherapies, especially among patient populations under-represented in clinical trials and in managing immune-related adverse events. This webinar will cover the current practices and challenges in management of metastatic melanoma, as well as insights on the future management of melanoma patients.

Take Course »

 

Credits: 1.00 AMA PRA Category 1 Credit™
2017 3A updates 116 x 141

KEEPING PACE WITH NEW AND EMERGING OPTIONS FOR MANAGING PSORIATIC ARTHRITIS GLOBAL LEARNING CENTER

Format: Webcast

The Global Learning Center provides you with free access to the latest peer-reviewed clinical information relating to the treatment of psoriatic arthritis. The Psoriatic Arthritis Global Learning Center is a freely accessible platform that aims to increase clinical knowledge by providing continuing medical educational activities, research articles and resources for healthcare providers who treat patients with psoriatic arthritis.

Take Course »

Credits: Earn Up to 2.75 AMA PRA Category 1 Credits™
116x140

Looking Beneath the Surface in Atopic Dermatitis: Targeting Immune Dysregulation and Delivering Comprehensive Care

Format: Webcast

This Interactive Exchange™ program will open with a brief 3D-animated video focused on the pathophysiologic underpinnings of atopic dermatitis. Expert faculty will then discuss best practices for comprehensive patient evaluations and the clinical profiles of systemic treatment options for patients with moderate-to-severe disease. With an overall goal of improving patient outcomes, this educational session has been designed to allow internationally recognized experts to translate the latest published evidence into actionable recommendations for individualized patient care.

Take Course »

Credits: 1.0 AMA PRA Category 1 Credit™
DERM 116x140

Perspectives from the American Academy of Dermatology 2017 Meeting: Clinical Strategies and Scientific Advances in Atopic Dermatitis

Format: Webcast

After many years of little movement in new therapies for patients with atopic dermatitis (AD), significant growth in researching the pathogenesis of AD has resulted in a better understanding of its causes, which has led to new protein targets for novel monoclonal antibodies (mABs). Often diagnosed in infancy, AD can persist into adulthood, affecting 3% to 5% of adults in the United States. Approximately 20% of children and adult patients have been diagnosed with moderate-to-severe AD. For this patient population, these latest advances continue to offer hope, as the current standard of care, which largely centers on symptom management, is suboptimal. This enduring video-based roundtable activity provides the latest updates on AD, including data on emerging and novel treatment options. Expert clinical faculty will also discuss the latest research in AD presented at the 41st Annual Hawaii Dermatology Seminar.  

Take Course »

Credits: 1.00 AMA PRA Category 1 Credit(s)™